Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K8/27—Zinc; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/74—Synthetic polymeric materials
  • A61K31/765—Polymers containing oxygen
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/74—Synthetic polymeric materials
  • A61K31/785—Polymers containing nitrogen
  • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/24—Heavy metals; Compounds thereof
  • A61K33/30—Zinc; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
  • A61K8/04—Dispersions; Emulsions
  • A61K8/06—Emulsions
  • A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K8/29—Titanium; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
  • A61K8/86—Polyethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/16—Emollients or protectives, e.g. against radiation
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
  • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/08—Anti-ageing preparations

Definitions

• the present invention relates to an external skin composition containing an ultraviolet wavelength converting substance and an alkylene oxide derivative, which has a cell activating action, and an ultraviolet wavelength converting function accelerator of the ultraviolet wavelength converting substance containing the alkylene oxide derivative as an active ingredient.
• UV rays are said to cause oxidation of sebum and damage to cellular DNA by generating free radicals in the body. Harmful effects on the skin caused by such action of ultraviolet rays include, for example, skin cancer, photoaging, spots, wrinkles, and inflammation, which are undesirable from the viewpoint of health and beauty.
• ultraviolet wavelength conversion substances not only reduce the harmful effects of ultraviolet rays, but also have a cell activating effect.
• an emulsified composition containing an ultraviolet wavelength-converting substance increases the concentration of cytochrome c in human skin-derived fibroblasts when irradiated with sunlight containing ultraviolet rays, and increases mitochondrial activity, thereby activating cells. (Patent Document 1).
• Alkylene oxide derivatives are known as non-sticky moisturizing agents and are used in external preparations for skin (Patent Document 2).
• the object of the present invention is to provide a novel composition for external use on the skin that has a cell activating effect using ultraviolet rays, and to provide an ultraviolet wavelength conversion function accelerator for an ultraviolet wavelength conversion substance containing an alkylene oxide derivative as an active ingredient.
• the inventors have conducted intensive research so that ultraviolet rays can be used effectively on the skin.
• an alkylene oxide derivative promotes the function of an ultraviolet wavelength converting substance, and a novel composition for external use on the skin with excellent cell activation action and an ultraviolet wavelength of an ultraviolet wavelength converting substance containing an alkylene oxide derivative as an active ingredient.
• I came up with the idea of a conversion function accelerator.
• An external skin composition comprising (A) an ultraviolet wavelength converting substance and (B) an alkylene oxide derivative represented by the following general formula (I): R 1 O—[(EO) m (AO) n ]—R 2 (I)
• AO is an oxyalkylene group having 3 to 4 carbon atoms
• EO is an oxyethylene group
• the oxyalkylene group having 3 to 4 carbon atoms and the oxyethylene group may be added blockwise or randomly
• m and n are the average number of added moles of the oxyethylene group and the oxyalkylene group, respectively, and 1 ⁇ m ⁇ 70, 1 ⁇ n ⁇ 70, and 0.2 ⁇ m/(m+n) ⁇ 0.8
• R 1 and R 2 are an alkyl group having 1 to 4 carbon atoms or a hydrogen atom, which may be the same or different;
• the external composition for skin according to [1], wherein the ultraviolet wavelength converting substance is one or more selected from zinc oxide phosphor, magnesium titanate phosphor, and phycocyanin.
• the external composition for skin according to [1] or [2], wherein the ultraviolet wavelength converting substance is a zinc oxide phosphor and phycocyanin.
• An ultraviolet wavelength conversion function accelerator for an ultraviolet wavelength conversion substance containing an alkylene oxide derivative represented by the following general formula (I) as an active ingredient: R 1 O—[(EO) m (AO) n ]—R 2 (I)
• AO is an oxyalkylene group having 3 to 4 carbon atoms
• EO is an oxyethylene group
• the oxyalkylene group having 3 to 4 carbon atoms and the oxyethylene group may be added blockwise or randomly
• R 1 and R 2 are an alkyl group having 1 to 4 carbon atoms or a hydrogen atom, which may be the same or different;
• AO is an oxyalkylene group having 3 to 4 carbon atoms
• EO is an oxyethylene group
• m and n are the average number of added moles of the oxyethylene group and the oxyalkylene group, respectively
• 1 ⁇ m ⁇ 70, 1 ⁇ n ⁇ 70, and 0.2 ⁇ m/(m+n) ⁇ 0.8 can be
• R 1 and R 2 are an alkyl group having 1 to 4 carbon atoms or a hydrogen atom, which may be the same or different;
• the ratio of the number of hydrogen atoms in R 1 and R 2 to the number of alkyl groups in R 1 and R 2 is 0.15 or less on
• the alkylene oxide derivative which is the ultraviolet wavelength conversion function accelerator according to the present invention, is suitable for the ultraviolet wavelength conversion substance to convert ultraviolet light into visible light, and can obtain strong emitted light (fluorescence).
• the composition for external use on the skin containing the alkylene oxide derivative of the present invention and an ultraviolet wavelength conversion substance emits strong fluorescence when irradiated with ultraviolet rays, and can effectively utilize ultraviolet rays to activate skin cells.
• ⁇ when applied to numerical values refers to a range of values that fall within the range of the specified reference value or more and the specified reference value or less.
• the external composition for skin of the present invention contains an ultraviolet wavelength converting substance as an active ingredient.
• An ultraviolet wavelength conversion material refers to a material that converts the wavelength of ultraviolet light contained in incident light and emits output light having a longer wavelength than the wavelength of the ultraviolet light.
• the organic ultraviolet wavelength conversion material refers to an ultraviolet wavelength conversion material that is an organic compound
• the inorganic ultraviolet wavelength conversion material refers to an ultraviolet wavelength conversion material that is an inorganic compound.
• Ultraviolet rays may include UVA, UVB, UVC, etc.
• ultraviolet light is light with a peak wavelength between 200 nm and 400 nm.
• incident light such as sunlight may contain ultraviolet rays.
• the incident light may be ultraviolet light, or artificially generated ultraviolet light may be used.
• the emitted light emitted by the ultraviolet wavelength conversion material has a longer wavelength than ultraviolet light, and preferably has a peak wavelength of 450 nm to 700 nm or 500 nm to 700 nm.
• the emitted light can be, for example, but not limited to, Alternatively, it may have one or more peaks within any range of these numerical values, or it may be red light, orange light, green light, blue light, or the like.
• the ultraviolet wavelength conversion material emits light with a dominant wavelength of 500 nm to 700 nm when excited with excitation light of 200 nm to 400 nm.
• ultraviolet wavelength conversion substances include the following components: phycocyanin (allophycocyanin, C-phycocyanin, R-phycocyanin), phycoerythrocyanin, phycoerythrin (B-phycoerythrin, b-phycoerythrin, C -Phycobiliproteins such as phycoerythrin, R-phycoerythrin); vitamin A, ⁇ -carotene, vitamin K, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, niacin, salicylic acid, lycopene, red pepper extract, red pepper pigment
• Naturally derived or synthetic ingredients such as paprika pigment, gardenia pigment, safflower pigment, turmeric pigment, cochineal pigment, perilla pigment, red cabbage pigment, flavonoids, carotenoids, quinoids, porphyrins, anthocyanins, and polyphenols; Red No.
• the inorganic phosphor is zinc oxide, which can be represented as ZnO: Zn, Zn 1+z , ZnO 1-x , such as zinc sulfide, zinc sulfate, etc., as described in WO 2018/004006.
• Phosphors doped with sulfur-containing compounds such as sulfides and/or sulfates Phosphors of magnesium titanate doped with manganese such as MgTiO 3 and Mg 2 TiO 4 (hereinafter referred to as phosphors derived from magnesium titanate is referred to as " magnesium titanate phosphor " ) ; There are more than one kind of phosphor.
• the inorganic ultraviolet wavelength conversion material which is an inorganic phosphor
• Surface treatments include, for example, silane compound treatment (octyltriethoxylan, etc.), silicone compound treatment, fluorine-modified silicone compound treatment, fluorine compound treatment, higher fatty acid treatment (stearic acid, etc.), higher alcohol treatment, fatty acid ester treatment, metallic soap. treatment, amino acid treatment, alkyl phosphate treatment and the like.
• the ultraviolet wavelength conversion substance may be obtained by a method such as extraction from natural products such as animals, plants, and algae, or may be obtained by an artificial method such as chemical synthesis.
• phycobiliproteins can be obtained from algae such as cyanobacteria such as Spirulina platensis and red algae such as Porphyridium purpureum by the methods described in Patent Nos. 4048420, 4677250 and 3303942. It may be prepared by extraction.
• the zinc oxide phosphor may be produced, for example, by the methods described in WO 2018/004006, JP-A-2018-131422, and JP-A-5-117127.
• the magnesium titanate phosphor may be produced by the method described in JP-A-2017-88719.
• a calcium phosphate phosphor may be produced by the method described in WO2018/117117.
• these ultraviolet wavelength conversion substances may be composed of or contained in the components exemplified above, and may be used alone or in combination of multiple types. good too.
• phycobiliproteins such as phycocyanin and inorganic phosphors such as zinc oxide phosphors may be included.
• phycobiliproteins and inorganic phosphors may contain other ultraviolet wavelength conversion substances such as vitamin B (vitamin B1, vitamin B2, vitamin B6, vitamin B12, etc.) may be mixed to achieve a synergistic effect.
• vitamin B vitamin B1, vitamin B2, vitamin B6, vitamin B12, etc.
• these components are examples, and any substance that exhibits the wavelength conversion effect of the present invention can be used.
• Vitamin B2 which is an ultraviolet wavelength conversion substance, may be a derivative thereof as long as it is an ultraviolet wavelength conversion substance.
• vitamin B2 derivatives include riboflavin acetate, riboflavin butyrate, riboflavin phosphate (which may be salts of sodium or monodiethanolamine), flavin mononucleotide, flavin adenine dinucleotide, riboflavin tetrabutyrate, riboflavin tetranicotinic acid.
• examples include esters, and derivatives of lyxoflavin, which is a stereoisomer of riboflavin.
• the content of the ultraviolet wavelength converting substance in the composition for external use on skin of the present invention is not particularly limited as long as it does not impair the wavelength conversion effect of the present invention. can be appropriately determined depending on the application. For example, 0.001 to 99.99% by weight, 0.001 to 10% by weight, 0.01 to 99.99% by weight, 0.01 to 10% by weight, 0.1% to 99.9% by weight, 0 .1 to 10% by weight or the like.
• the ultraviolet wavelength converting substance in the external composition for skin contains a zinc oxide phosphor
• the preferred zinc oxide phosphor content in the external composition for skin of the present invention is is 0.1% by weight or more, preferably 1.0% by weight or more, more preferably 1.5% by weight or more, still more preferably 2% by weight or more, and 20% by weight or less. , preferably 15% by weight or less, more preferably 10% by weight or less, and still more preferably 5% by weight or less, and 0.01 to 99.99% by weight, 0.1 ⁇ 99.9% by weight, 0.1-50% by weight, 0.1-40% by weight, 0.1-30% by weight, 0.1-20% by weight, 0.1-10% by weight or 1-10% by weight % by weight.
• the ultraviolet wavelength converting substance in the external composition for skin contains a magnesium titanate phosphor
• the preferred content of the magnesium titanate phosphor in the external composition for skin of the present invention is It is 0.1% by weight or more, preferably 1.0% by weight or more, more preferably 1.5% by weight or more, still more preferably 2% by weight or more, and 20% by weight or less based on the whole , preferably 15% by weight or less, more preferably 10% by weight or less, and even more preferably 5% by weight or less, and 0.01 to 99.99% by weight, based on the entire external composition for skin. .1-99.9% by weight, 0.1-50% by weight, 0.1-40% by weight, 0.1-30% by weight, 0.1-20% by weight, 0.1-10% by weight, 0 .5 to 10% by weight or 1 to 10% by weight.
• the ultraviolet wavelength converting substance in the external composition for skin contains phycocyanin
• the preferred content of phycocyanin in the external composition for skin of the present invention is 0.00001 weight relative to the entire external composition for skin. % or more, preferably 0.0001% by mass or more, and 20% by weight or less, preferably 15% by weight or less, more preferably 10% by weight or less, and still more preferably 5% by weight or less.
• the ultraviolet wavelength converting substance in the external composition for skin contains vitamin B2, and the content of vitamin B2 in the external composition for skin of the present invention is preferably 0.005% relative to the entire external composition for skin.
• 00001% by weight or more preferably 0.0001% by weight or more, and 20% by weight or less, preferably 15% by weight or less, more preferably 10% by weight or less, and still more preferably 5% by weight 0.00001 to 99.99% by weight, 0.0001 to 99.9% by weight, 0.0001 to 50% by weight, 0.0001 to 40% by weight, 0 0.0001-30% by weight, 0.0001-20% by weight, 0.0001-10% by weight, 0.0001-5% by weight, 0.001-5% by weight, 0.005-5% by weight, 0.01 ⁇ 5 wt%, 0.01-1 wt%, 0.01-0.5 wt% or 0.01-0.1 wt%.
• Cell activation refers to, but is not limited to, animal cells including humans, such as skin fibroblasts and / or keratinocyte metabolism and turnover promotion, function improvement, proliferation promotion, oxidation suppression, fatigue and improvement of tolerance to external stimuli, suppression of decline in function and activity, etc.
• skin cells are activated, effects such as prevention and improvement of wrinkles, spots, skin aging, photoaging, etc. are expected.
• the cell activation effect may be measured by measuring the survival rate, reduction ability and proliferation of living cells using Alamar Blue, as in Patent Document 1, for example, or by measuring other dye assays, mitochondrial membrane potential difference, etc.
• composition for external use on the skin of the present invention is suitable for exhibiting the function of an ultraviolet wavelength conversion substance, and by activating cells, alleviates damage to the skin during and after irradiation with ultraviolet rays, or more actively improves and recovers the skin.
• the fluorescence intensity may be measured by, for example, using a spectrofluorometer to measure the fluorescence intensity when a plate containing the external composition for skin is irradiated with ultraviolet rays, or by forming a coating film of the composition on the surface of the substrate.
• the fluorescence intensity when irradiated with ultraviolet rays can also be measured using a spectrofluorometer.
• a resin substrate such as polymethyl methacrylate (PMMA), nylon or acrylic plate, or an inorganic substrate such as glass or quartz can be used.
• plate see Japanese Patent No. 4453995
• the measurement of fluorescence intensity may be a fluorescence value of a specific single wavelength or an integrated value of a specific wavelength range.
• an alkylene oxide derivative especially an alkylene oxide derivative represented by the following formula (I).
• AO is an oxyalkylene group having 3 to 4 carbon atoms
• EO is an oxyethylene group
• m and n are the average number of added moles of the oxyethylene group and the oxyalkylene group, respectively, and 1 ⁇ m ⁇ 70, 1 ⁇ n ⁇ 70.
• the ratio of the oxyethylene group to the total of the oxyalkylene group having 3 to 4 carbon atoms and the oxyethylene group is 20 to 80% by mass (0.2 ⁇ m/(m + n) ⁇ 0 .8)
• the oxyalkylene group having 3 to 4 carbon atoms and the oxyethylene group may be added in a block or random fashion, and R 1 and R 2 may be the same or different carbon atoms. 1 to 4 hydrocarbon groups or hydrogen atoms, and the ratio of the number of hydrogen atoms to the number of hydrocarbon groups of R 1 and R 2 is 0.15 or less on average.)
• AO is an oxyalkylene group having 3 to 4 carbon atoms, specifically oxypropylene group, oxybutylene group, oxyisobutylene group, oxytrimethylene group, oxytetramethylene group. etc. Oxypropylene group and oxybutylene group are preferred.
• EO is an oxyethylene group.
• m is the average number of added moles of oxyethylene groups, and 1 ⁇ m ⁇ 70, preferably 2 ⁇ m ⁇ 50.
• n is the average number of added moles of oxyalkylene groups having 3 to 4 carbon atoms, and satisfies 1 ⁇ n ⁇ 70, preferably 5 ⁇ n ⁇ 55.
• the ratio of oxyethylene groups to the total of oxyalkylene groups having 3 to 4 carbon atoms and oxyethylene groups is preferably 20 to 80% by mass.
• the order of addition of ethylene oxide and alkylene oxide having 3 to 4 carbon atoms is not particularly specified.
• the oxyethylene group and the oxyalkylene group having 3 to 4 carbon atoms may be added in a block form or in a random form. Preferably, those added in a random manner are mentioned.
• R 1 and R 2 are hydrocarbon groups having 1 to 4 carbon atoms or hydrogen atoms, and the hydrocarbon groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, Alkyl groups such as a tert-butyl group are included. Methyl group and ethyl group are preferred. Hydrocarbon groups having 5 or more carbon atoms tend to reduce the effects of the present invention. R 1 and R 2 may be the same or different.
• Each of R 1 and R 2 may be used alone, or a mixture of a hydrocarbon group having 1 to 4 carbon atoms and a hydrogen atom, or a mixture of hydrocarbon groups having 1 to 4 carbon atoms.
• the abundance ratio of the hydrocarbon group and the hydrogen atom is such that the ratio Y/X of the number of hydrogen atoms (Y) to the number of hydrocarbon groups (X) is 0 on average. 0.15 or less, preferably 0.06 or less on average.
• the alkylene oxide derivative of formula (I) can be produced by a known method. For example, it can be obtained by subjecting a compound having a hydroxyl group to addition polymerization of ethylene oxide and an alkylene oxide having 3 to 4 carbon atoms, followed by an ether reaction with an alkyl halide in the presence of an alkali catalyst.
• alkylene oxide derivative of formula (I) examples include POE (9) POP (2) dimethyl ether, POE (14) POP (7) dimethyl ether, POE (10) POP (10) dimethyl ether, POE (6) POP ( 14) dimethyl ether, POE (15) POP (5) dimethyl ether, POE (25) POP (25) dimethyl ether, POE (7) POP (12) dimethyl ether, POE (22) POP (40) dimethyl ether, POE (35) POP ( 40) dimethyl ether, POE (50) POP (40) dimethyl ether, POE (55) POP (30) dimethyl ether, POE (30) POP (34) dimethyl ether, POE (25) POP (30) dimethyl ether, POE (27) POP ( 14) dimethyl ether, POE (55) POP (28) dimethyl ether, POE (36) POP (41) dimethyl ether, POE (7) POP (12) dimethyl ether, POE (17) POP (4) dimethyl ether, POE (
• polyoxyethylene (POE)/polyoxypropylene (POP) dimethyl ether is preferably used, but not limited thereto.
• POE, POP, and POB are abbreviations for polyoxyethylene, polyoxypropylene, and polyoxybutylene, respectively.
• alkylene oxide derivatives in the present invention can be arbitrarily selected and used.
• the inclusion of oxyethylene (14) polyoxypropylene (7) dimethyl ether is particularly preferred.
• the content of the alkylene oxide derivative in the external composition for skin of the present invention is preferably 0.1% by weight or more, preferably 0.5% by weight or more, more preferably 1% by weight, based on the total external composition for skin. or more, and 20% by weight or less, preferably 10% by weight or less, more preferably 5% by weight or less, and 0.01 to 99.99% by weight, 0.1 to 99% .9% by weight, 0.1-20% by weight, 0.1-10% by weight, 0.1-5% by weight, 0.5-20% by weight, 0.5-10% by weight, 0.5-5% by weight % by weight, 1-20% by weight, 1-10% by weight, or 1-5% by weight.
• the composition for external use on skin of the present invention can contain the following components.
• the composition for external use on skin of the present invention contains an ultraviolet absorber.
• a UV absorber refers to a substance that absorbs UV rays, changes them into energy such as heat or infrared rays, and emits them.
• the UV absorber that can be used in the present invention is not particularly limited as long as it does not directly impair the function of the UV wavelength conversion substance.
• UV absorber 2-ethylhexyl paramethoxycinnamate, glyceryl mono-2-ethylhexanoate di-paramethoxycinnamate, methyl 2,5-diisopropylcinnamate, 2,4,6-tris[4-(2-ethylhexyl) oxycarbonyl)anilino]-1,3,5-triazine (hereinafter also referred to as "ethylhexyltriazone”), methylbis(trimethylsiloxy)silylisopentyl trimethoxycinnamate, isopropyl/diisopropyl paramethoxycinnamate Cinnamic acid-based UV absorbers such as acid ester mixtures and p-methoxyhydrocinnamic acid diethanolamine salts; Benzoylmethane-based UV absorbers such as 2-phenyl-benzimidazole-5-sulfuric acid, 4-isopropyl
• the total content of ultraviolet absorbers that can be contained in the external composition for skin of the present invention is 0.5% by weight or more, preferably 1% by weight, based on the total external composition for skin in order to function as a sunscreen. above, more preferably 5% by weight or more, still more preferably 8% by weight or more, and most preferably 10% by weight or more. , 40% by weight or less, preferably 30% by weight or less, more preferably 25% by weight or less, and even more preferably 20% by weight or less, relative to the entire external composition for skin.
• the range of the content of the entire UV absorber that can be contained in the composition for external use on the skin of the present invention is 0.5 to 40% by weight, 1 to 40% by weight, 1 to 30% by weight, 1 to 25% by weight, and 1 to 40% by weight. 20 wt%, 5-40 wt%, 5-30 wt%, 5-25 wt%, 5-20 wt%, 8-30 wt%, 8-25 wt%, or 8-20 wt%.
• UV scattering agent Since the ultraviolet scattering agent scatters incident ultraviolet rays, it is thought that it indirectly inhibits the function of the ultraviolet wavelength conversion substance.
• the composition for external use on skin of the present invention may contain an ultraviolet scattering agent.
• a UV scattering agent refers to a substance capable of reflecting and scattering UV rays to protect the skin and the like from UV rays.
• Materials for the ultraviolet scattering agent that can be used in the present invention include titanium oxide, zinc oxide other than component (A), iron oxide, zirconium oxide, and aluminum oxide.
• an ultraviolet scattering agent those obtained by making these materials into fine particles or compounding them can be mentioned.
• the ultraviolet scattering agent preferably contains one or more selected from titanium oxide and zinc oxide other than component (A).
• the titanium oxide and zinc oxide used as UV scattering agents may be titanium oxide and zinc oxide that are commonly used in cosmetics.
• a composition having better dispersibility for example, a surface-treated, specifically hydrophobicized, surface-treated composition can be contained in the composition for external use on the skin, if necessary.
• Examples of surface treatment methods include silicone treatment with methylhydrogenpolysiloxane, methylpolysiloxane, etc.; fluorine treatment with perfluoroalkyl phosphate, perfluoroalcohol, etc.; amino acid treatment with N-acylglutamic acid, etc.; octyltriethoxysilane, octyl. treatment with alkylalkoxysilane such as trimethoxysilane; treatment with stearic acid/aluminum hydroxide; treatment with lecithin; treatment with metallic soap; treatment with fatty acid; Among them, zinc oxide whose surface is treated with silicone is preferably used.
• Silicones used for surface treatment are not limited, but examples include methylpolysiloxane, methylphenylpolysiloxane, methylhydrogenpolysiloxane, methylcyclopolysiloxane, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane, octa Methyltrisiloxane, tetradecamethylhexasiloxane, dimethylsiloxane/methyl (polyoxyethylene) siloxane/methyl (polyoxypropylene) siloxane copolymer, dimethylsiloxane/methyl (polyoxyethylene) siloxane copolymer, dimethylsiloxane/methyl Various silicones such as (polyoxypropylene) siloxane copolymers, dimethylsiloxane/methylcetyloxysiloxane copolymers, and
• octyltriethoxysilane-treated zinc oxide can facilitate redispersion of precipitates and aggregates of metal compound particles with a large specific gravity.
• the total content of the ultraviolet scattering agent that can be contained in the external composition for skin of the present invention is 0.1% by weight or more, preferably 0.5% by weight, based on the total external composition for skin in order to function as a sunscreen.
• the range of the total content of the ultraviolet scattering agent that can be contained in the composition for external use on the skin of the present invention is 0.1 to 40% by weight, 0.1 to 30% by weight, 0.1 to 25% by weight, and 0.1 to 0.1% by weight.
• the composition for external use on skin of the present invention may contain powder.
• Powder refers to a very finely divided solid substance.
• the powder contained in the external composition for skin of the present invention is not particularly limited as long as it is commonly used in cosmetics. Examples include polymethyl methacrylate, crosslinked silicone/network silicone block copolymer, Examples include silica, hydrophobized talc, corn starch, and hydrophobized polyurethane. All or part of the powder is dispersed in the oil phase of the external composition for skin of the present invention.
• the amount of the powder that can be contained in the external composition for skin of the present invention is 0.01% by weight or more, preferably 0.05% by weight or more, more preferably 0.1% by weight, based on the total external composition for skin. above, more preferably 0.5% by weight or more, and 20% by weight or less, preferably 15% by weight or less, more preferably 10% by weight or less, and still more preferably 5% by weight or less Yes, and 0.01 to 99.99% by weight, 0.1 to 99.9% by weight, 0.1 to 20% by weight, 0.1 to 15% by weight, and 0.1% of the total external composition for skin ⁇ 10 wt%, 0.5-20 wt%, 0.5-10 wt% or 1-10 wt%.
• the composition for external use on skin of the present invention may contain a dispersant.
• a dispersant refers to a substance that can be uniformly dispersed in an aqueous or oily medium by adsorbing onto the surface of particles dispersed in an aqueous or oily phase.
• the dispersant that can be used in the present invention is not particularly limited as long as it does not impair the function of the ultraviolet wavelength conversion substance, and is preferably an oil-based dispersant. Active agents, anionic surfactants, silicone-based surfactants, fatty acids and the like can be mentioned. In the present invention, it is particularly preferred to use nonionic surfactants and/or silicone surfactants and/or fatty acids that are commonly used in cosmetics and pharmaceuticals.
• Preferred dispersants that can be contained in the external composition for skin of the present invention include PEG-10 dimethicone, bisbutyl dimethicone polyglyceryl-3, PEG-polydimethylpolysiloxane ethyl dimethicone, lauryl PEG-polydimethylpolysiloxane ethyl dimethicone, and cetyl PEG. /PPG-10/dimethicone, isostearic acid, polyglyceryl-2 diisostearate, carboxydecyltrisiloxane, PEG-12 dimethicone, or polyoxyethylene sorbitan monostearate or combinations of two or more thereof.
• Preferred examples of dispersants that can be contained in the composition for external use on skin of the present invention include PEG-10 dimethicone, bisbutyldimethicone polyglyceryl-3, and PEG-9 polydimethylpolysiloxy, since they enhance the function of the ultraviolet wavelength conversion substance. Included are ethyl dimethicone, lauryl PEG-9 polydimethylpolysiloxyethyl dimethicone, cetyl PEG/PPG-10/1 dimethicone, isostearic acid, carboxydecyltrisiloxane, or combinations of two or more thereof.
• the content of the dispersant in the external composition for skin of the present invention is not particularly limited as long as it does not impair the wavelength conversion effect of the present invention. can be determined as appropriate. For example, it is arbitrary within the range of 0.01 to 10% by weight, 0.1% to 99.9% by weight, and the like.
• the content of the dispersant in the external composition for skin of the present invention is preferably 0.1% by weight or more, preferably 0.3% by weight or more, more preferably 0.5% by weight, based on the total external composition for skin. % or more, and 20% by weight or less, preferably 10% by weight or less, more preferably 5% by weight or less, even more preferably 2% by weight or less, and 0.01 to 0.01% based on the whole 99.99% by weight, 0.1-99.9% by weight, 0.1-20% by weight, 0.1-10% by weight, 0.1-5% by weight, 0.1-3% by weight, 0.1-3% by weight; 1-2% by weight, 0.1-1% by weight, 0.5-10% by weight, 0.5-5% by weight or 0.5-2% by weight.
• the dispersant in the external composition for skin contains bisbutyl dimethicone polyglyceryl-3 (KF-6109 manufactured by Shin-Etsu Chemical Co., Ltd.), and the content of the dispersant in the external composition for skin is It is 0.1% by weight or more, preferably 0.3% by weight or more, more preferably 0.5% by weight or more, and 20% by weight or less, preferably 10% by weight, based on the total composition for external use.
• % by weight or less more preferably 5% by weight or less, still more preferably 2% by weight or less, and 0.01 to 99.99% by weight, 0.1 to 99.9% by weight, based on the total composition for external use on skin % by weight, 0.1-20% by weight, 0.1-10% by weight, 0.1-5% by weight, 0.1-3% by weight, 0.1-2% by weight, 0.1-1% by weight , 0.5-10% by weight, 0.5-5% by weight or 0.5-2% by weight.
• Oil refers to a hydrophobic substance that phase-separates from water, which is a component of the composition for external use on skin of the present invention.
• Oils that can be used in the present invention are not particularly limited, and include, for example, at least one or more of hydrocarbon oils, ester oils, silicone oils, liquid fats, solid fats and higher alcohols.
• Hydrocarbon oils include liquid paraffin, tetraisobutane, hydrogenated polydecene, olefin oligomers, isododecane, isohexadecane, squalane, and hydrogenated polyisobutene.
• Ester oils include alkyl (C 12-15 ) benzoate, diisopropyl sebacate, octyl palmitate, cetyl isooctanoate (cetyl 2-ethylhexanoate), triethylhexanoin, neopentyl glycol dicaprate, triisostearin, malic acid.
• diisostearyl, PPG-3 dipivalate, di-2-ethylhexyl succinate, 2-ethylhexyl 2-ethylhexanoate, polyglyceryl-6 octacaprylate, tri(caprylic/capric)glyceryl and the like.
• silicone oils examples include caprylylmethicone, dimethicone, amino-modified polysiloxane, polyether-modified polysiloxane, alkyl-modified polysiloxane, and fluorine-modified polysiloxane.
• Liquid fats and oils include avocado oil, camellia oil, macadamia nut oil, mink oil, olive oil, castor oil, jojoba oil, triglycerin, glycerin trioctanoate, isostearic acid, and the like.
• Solid fats and oils include coconut oil, hardened coconut oil, palm oil, beef tallow, mutton fat, Japanese wax, and hardened castor oil.
• higher alcohols examples include isostearyl alcohol, oleyl alcohol, copolymers of butylene glycol and propylene glycol (for example, PBG/PPG-9/1 copolymer).
• the total oil content in the external composition for skin of the present invention is 5% by weight or more, preferably 10% by weight or more, and more preferably 15% by weight or more, relative to the total external composition for skin.
• Oil Phase Thickener The composition for external use on skin of the present invention may contain an oil phase thickener.
• the oil phase thickener is an additive capable of increasing the viscosity of the liquid of the oil phase by dissolving it in the oil phase of the composition for external use on skin.
• Oil phase thickeners include sugar fatty acid esters, solid oils, metal soaps, 12-hydroxystearic acid, bentonite, hectorite (eg, dimethyldistearylammonium hectorite) and other inorganic polymers.
• sugar fatty acid esters include esters of fatty acids having 10 to 22 carbon atoms with dextrin, sucrose (e.g., sucrose triacetate tetrastearate), inulin, etc.
• dextrin palmitate and myristin include dextrin palmitate and myristin.
• sucrose tetrastearate triacetate, dimethyldistearyl ammonium hectorite, dextrin palmitate, dextrin myristate, (palmitate/ethylhexanoate) dextrin, and inulin stearate are particularly useful in terms of usability and stability. preferable.
• One or two or more selected from these can be included in the composition for external use on the skin.
• composition for external use on the skin of the present invention can contain various components as appropriate within a range that does not affect the effects of the present invention.
• various components include additive components that can be usually blended in cosmetics, such as powder ((spherical) silica, polymethyl methacrylate, crosslinked silicone/network silicone block copolymer, talc (dimethicone-treated corn starch, polyurethane, etc.), chelating agent (edetate sodium hydrate, etc.), fragrance, moisturizing agent other than (B) (glycerin, dipropylene glycol, PEG-6, etc.), preservative, anionic Surfactants, cationic surfactants, amphoteric surfactants, nonionic surfactants, moisturizing agents, water-soluble polymers, siliconized polysaccharides, (acrylamide/DMAPA acrylate/methoxy PEG methacrylate) copolymers, etc.
• Film-forming agents sequestering agents, lower alcohols, polyhydric alcohols, extracts, sugars, amino acids, organic amines, polymer emulsions, pH adjusters, skin nutrients, vitamins, pharmaceuticals, quasi-drugs, cosmetics, etc. water-soluble agents (tranexamic acid, niacinamide, potassium 4-methoxysalicylate, dipotassium glycyrrhizinate, etc.), antioxidants, buffers, antioxidant aids, propellants, pigments, dyes, pigments, water, acids components, alkaline components, and the like. These optional components can be appropriately blended in the oil phase and the water phase. Furthermore, in order to enhance the effects of the present invention, other cell activating agents may be contained or used in combination.
• the composition for external use on skin of the present invention can be produced according to a normal production method.
• the external composition for skin according to the present embodiment is obtained by the following procedure.
• Component (B) and water are mixed to prepare an aqueous phase, and component (A) or (A') is mixed when dispersing in the aqueous phase.
• An oily component such as an oil component is mixed to prepare an oil phase, and (A) or (A') is mixed when dispersing in the oil phase.
• An oil phase and other ingredients are added to the water phase and stirred to obtain a composition for external use on skin.
• the composition for external use on the skin of the present invention includes sunscreen cosmetics such as sunscreen cream. Moreover, as a dosage form, it can be set as milky lotions, creams, etc., for example.
• the external composition for skin of the present invention gives a refreshing feeling in use compared to the water-in-oil type, and has a unique fresh feeling in use that melts and crumbles when applied to the skin.
• the composition for external use on the skin of the present invention can be used by applying, preferably coating, to the skin, especially the skin excluding the hair, preferably the face, body, hands and feet.
• the composition for external use to the skin of the present embodiment it not only protects the skin from ultraviolet rays and suppresses adverse effects on the skin, but also activates skin cells and is natural and preferable for the skin. Appearance can also be given.
• Ultraviolet Wavelength Conversion Function Accelerator One aspect of the present invention is an alkylene oxide derivative as an ultraviolet wavelength conversion function accelerator.
• the "ultraviolet wavelength conversion function accelerator” means that although the compound itself has no ultraviolet wavelength conversion activity, it can enhance the ultraviolet wavelength conversion function of the ultraviolet wavelength conversion substance in a composition containing the ultraviolet wavelength conversion substance. means a compound that can
• the fact that the alkylene oxide derivative is an ultraviolet wavelength conversion function accelerator can be confirmed by adding the alkylene oxide derivative to a composition containing an ultraviolet wavelength converting substance and increasing the fluorescence intensity when the composition is irradiated with ultraviolet light.
• the fluorescence intensity may be measured by, for example, using a spectrofluorometer to measure the fluorescence intensity when a plate containing the external composition for skin is irradiated with ultraviolet rays, or by forming a coating film of the composition on the surface of the substrate.
• the fluorescence intensity when irradiated with ultraviolet rays can also be measured using a spectrofluorometer.
• a resin substrate such as polymethyl methacrylate (PMMA), nylon or acrylic plate, or an inorganic substrate such as glass or quartz can be used. Also referred to as "plate”: see Japanese Patent No. 4453995) and the like can be used.
• the measurement of fluorescence intensity may be a fluorescence value of a specific single wavelength or an integrated value of a specific wavelength range.
• alkylene oxide derivative as the ultraviolet wavelength conversion function accelerator of the present invention, it is particularly preferable to use an alkylene oxide derivative represented by the following formula (I).
• AO is an oxyalkylene group having 3 to 4 carbon atoms
• EO is an oxyethylene group
• m and n are the average number of added moles of the oxyethylene group and the oxyalkylene group, respectively, and 1 ⁇ m ⁇ 70, 1 ⁇ n ⁇ 70.
• the ratio of the oxyethylene group to the total of the oxyalkylene group having 3 to 4 carbon atoms and the oxyethylene group is 20 to 80% by mass (0.2 ⁇ m/(m + n) ⁇ 0 .8)
• the oxyalkylene group having 3 to 4 carbon atoms and the oxyethylene group may be added in a block or random fashion, and R 1 and R 2 may be the same or different carbon atoms. 1 to 4 hydrocarbon groups or hydrogen atoms, and the ratio of the number of hydrogen atoms to the number of hydrocarbon groups of R 1 and R 2 is 0.15 or less on average.)
• AO is an oxyalkylene group having 3 to 4 carbon atoms, specifically oxypropylene group, oxybutylene group, oxyisobutylene group, oxytrimethylene group, oxytetramethylene group. etc. Oxypropylene group and oxybutylene group are preferred.
• EO is an oxyethylene group.
• m is the average number of added moles of oxyethylene groups, and 1 ⁇ m ⁇ 70, preferably 2 ⁇ m ⁇ 50.
• n is the average number of added moles of oxyalkylene groups having 3 to 4 carbon atoms, and satisfies 1 ⁇ n ⁇ 70, preferably 5 ⁇ n ⁇ 55.
• the ratio of oxyethylene groups to the total of oxyalkylene groups having 3 to 4 carbon atoms and oxyethylene groups is preferably 20 to 80% by mass.
• the order of addition of ethylene oxide and alkylene oxide having 3 to 4 carbon atoms is not particularly specified.
• the oxyethylene group and the oxyalkylene group having 3 to 4 carbon atoms may be added in a block form or in a random form. Preferably, those added in a random manner are mentioned.
• R 1 and R 2 are hydrocarbon groups having 1 to 4 carbon atoms or hydrogen atoms, and the hydrocarbon groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, Alkyl groups such as a tert-butyl group are included. Methyl group and ethyl group are preferred. Hydrocarbon groups having 5 or more carbon atoms tend to reduce the effects of the present invention. R 1 and R 2 may be the same or different.
• Each of R 1 and R 2 may be used alone, or a mixture of a hydrocarbon group having 1 to 4 carbon atoms and a hydrogen atom, or a mixture of hydrocarbon groups having 1 to 4 carbon atoms.
• the abundance ratio of the hydrocarbon group and the hydrogen atom is such that the ratio Y/X of the number of hydrogen atoms (Y) to the number of hydrocarbon groups (X) is 0 on average. 0.15 or less, preferably 0.06 or less on average.
• the alkylene oxide derivative of formula (I) can be produced by a known method. For example, it can be obtained by subjecting a compound having a hydroxyl group to addition polymerization of ethylene oxide and an alkylene oxide having 3 to 4 carbon atoms, followed by an ether reaction with an alkyl halide in the presence of an alkali catalyst.
• alkylene oxide derivative of formula (I) examples include POE (9) POP (2) dimethyl ether, POE (14) POP (7) dimethyl ether, POE (10) POP (10) dimethyl ether, POE (6) POP ( 14) dimethyl ether, POE (15) POP (5) dimethyl ether, POE (25) POP (25) dimethyl ether, POE (7) POP (12) dimethyl ether, POE (22) POP (40) dimethyl ether, POE (35) POP ( 40) dimethyl ether, POE (50) POP (40) dimethyl ether, POE (55) POP (30) dimethyl ether, POE (30) POP (34) dimethyl ether, POE (25) POP (30) dimethyl ether, POE (27) POP ( 14) dimethyl ether, POE (55) POP (28) dimethyl ether, POE (36) POP (41) dimethyl ether, POE (7) POP (12) dimethyl ether, POE (17) POP (4) dimethyl ether, POE (
• polyoxyethylene (POE)/polyoxypropylene (POP) dimethyl ether is preferably used, but not limited thereto.
• POE, POP, and POB are abbreviations for polyoxyethylene, polyoxypropylene, and polyoxybutylene, respectively.
• alkylene oxide derivatives in the present invention can be arbitrarily selected and used.
• the inclusion of oxyethylene (14) polyoxypropylene (7) dimethyl ether is particularly preferred.
• the content of the alkylene oxide derivative as the ultraviolet wavelength conversion function accelerator of the present invention in the composition containing the ultraviolet wavelength conversion substance is 0.1% by weight or more, preferably 0.1% by weight, based on the total composition. 5% by weight or more, more preferably 1% by weight or more, and 20% by weight or less, preferably 10% by weight or less, more preferably 5% by weight or less, and 0.01 to 99.99% by weight, 0.1-99.9% by weight, 0.1-20% by weight, 0.1-10% by weight, 0.1-5% by weight, 0.5-20% by weight; 5-10% by weight, 0.5-5% by weight, 1-20% by weight, 1-10% by weight, or 1-5% by weight.
• Examples of ultraviolet wavelength conversion substances in which the alkylene oxide derivative of the present invention acts as an ultraviolet wavelength conversion function accelerator include the following components: phycocyanin (allophycocyanin, C-phycocyanin, R-phycocyanin), phycoerythrocyanin, Phycobiliproteins such as phycoerythrin (B-phycoerythrin, b-phycoerythrin, C-phycoerythrin, R-phycoerythrin); vitamin A, ⁇ -carotene, vitamin K, vitamin B1, vitamin B2, vitamin B6 , vitamin B12, folic acid, niacin, salicylic acid, lycopene, red pepper extract, red pepper pigment, paprika pigment, gardenia pigment, safflower pigment, turmeric pigment, cochineal pigment, perilla pigment, red cabbage pigment, flavonoids, carotenoids, quinoids, porphyrins, anthocyanins naturally derived or synthetic components such as polyphenols; , 2,
• the inorganic phosphor is zinc oxide, which can be represented as ZnO: Zn, Zn 1+z , ZnO 1-x , such as zinc sulfide, zinc sulfate, etc., as described in WO 2018/004006.
• Phosphors doped with sulfur-containing compounds such as sulfides and/or sulfates Phosphors of magnesium titanate doped with manganese such as MgTiO 3 and Mg 2 TiO 4 (hereinafter referred to as phosphors derived from magnesium titanate is referred to as " magnesium titanate phosphor " ) ; There are more than one kind of phosphor.
• alkylene oxide derivatives to facilitate the function of UV wavelength converting materials.
• An alkylene oxide derivative can be added as a component of the composition containing the ultraviolet wavelength converting material.
• an alkylene oxide derivative represented by the following formula (I).
• R 1 O—[(EO) m (AO) n ]—R 2 (I) (Wherein, AO is an oxyalkylene group having 3 to 4 carbon atoms, EO is an oxyethylene group, m and n are the average number of added moles of the oxyethylene group and the oxyalkylene group, respectively, and 1 ⁇ m ⁇ 70, 1 ⁇ n ⁇ 70.
• the ratio of the oxyethylene group to the total of the oxyalkylene group having 3 to 4 carbon atoms and the oxyethylene group is 20 to 80% by mass (0.2 ⁇ m/(m + n) ⁇ 0 .8)
• the oxyalkylene group having 3 to 4 carbon atoms and the oxyethylene group may be added in a block or random fashion, and R 1 and R 2 may be the same or different carbon atoms. 1 to 4 hydrocarbon groups or hydrogen atoms, and the ratio of the number of hydrogen atoms to the number of hydrocarbon groups of R 1 and R 2 is 0.15 or less on average.)
• the alkylene oxide derivative of the present invention exhibits excellent effects as an ultraviolet wavelength conversion function accelerator is not clear, it functions as a moisturizing agent and has two different properties such as POE (14) and POP (7).
• the alkylene oxide derivative increases the affinity between the ultraviolet wavelength conversion substance and the base material, and the ultraviolet wavelength conversion substance may be uniformly dispersed in the base material to efficiently convert the wavelength of the irradiated ultraviolet light. .
• Example 1 Effect of POE (14) POP (7) dimethyl ether on UV wavelength conversion substance
• External skin compositions (formulation examples A and B) having the composition shown in Table 1 were produced according to a conventional production method.
• the POE (14) POP (7) dimethyl ether used was one in which oxypropylene groups and oxyethylene groups were randomly added.
• each external composition for skin contains an octyltriethoxysilane-treated zinc oxide phosphor as an ultraviolet wavelength conversion substance.
• the resulting composition for external use on skin was irradiated with ultraviolet light having a wavelength of 365 nm, and the integrated fluorescence value from 400 to 600 nm was measured using a spectrofluorophotometer RF-5300PC (Shimadzu Corporation).
• Example 2 Effect of moisturizing agent on ultraviolet wavelength conversion substance (zinc oxide phosphor) Compositions for external use on the skin (formulation examples C to F) having the compositions shown in Table 2 were produced according to a conventional production method.
• Formulation C does not contain a humectant
• Formulation D contains 1% POE(14)POP(7) dimethyl ether (randomly added)
• Formulation E contains 2% glycerin
• Formulation F contains 2% PEG-6.
• Example 3 Effect of moisturizing agent on ultraviolet wavelength conversion substance (zinc oxide phosphor + phycocyanin)
• Skin external preparations containing phycocyanin (LinaBlue, manufactured by DIC), which is an organic phosphor and has long-wavelength fluorescence, together with a zinc oxide phosphor were produced according to a conventional production method (formulation examples G and H).
• Formulation G contains no humectant
• Formulation H contains 2% POE(14)POP(7) dimethyl ether (randomly added).
• the resulting composition for external use on skin was irradiated with ultraviolet rays having a wavelength of 350 nm, and the integrated fluorescence value from 400 to 800 nm was measured using a spectrofluorophotometer RF-5300PC (Shimadzu Corporation).
• POE(14)POP(7) dimethyl ether enhanced the UV wavelength conversion function of octyltriethoxysilane-treated zinc oxide phosphor and LinaBlue (Table 3).
• POE(14)POP(7) dimethyl ether has the property of being infinitely miscible in both water and polar oil, despite its relatively large molecular weight. With the configuration having .
• compositions for external use on the skin and the ultraviolet wavelength conversion function accelerator of the present invention have been described above.
• present invention is not limited to these, and can be modified as appropriate without departing from the gist of the invention.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Birds (AREA)
• Inorganic Chemistry (AREA)
• Dermatology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gerontology & Geriatric Medicine (AREA)
• Toxicology (AREA)
• Dispersion Chemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Botany (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Cosmetics (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=84426002

Family Applications (1)

Country Status (5)

Citations (16)

Family Cites Families (8)

• 2022
  • 2022-05-26 JP JP2023527611A patent/JPWO2022259884A1/ja active Pending
  • 2022-05-26 CN CN202280034084.3A patent/CN117279610A/zh active Pending
  • 2022-05-26 EP EP22820066.3A patent/EP4353325A4/en active Pending
  • 2022-05-26 WO PCT/JP2022/021651 patent/WO2022259884A1/ja not_active Ceased
  • 2022-05-26 US US18/559,940 patent/US20240390242A1/en active Pending

Patent Citations (16)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events